Cara Therapeutics, Inc. (NASDAQ:CARA) – Investment analysts at Jefferies Financial Group boosted their FY2021 EPS estimates for shares of Cara Therapeutics in a research report issued to clients and investors on Monday, May 10th. Jefferies Financial Group analyst C. Howerton now anticipates that the biopharmaceutical company will post earnings of ($2.54) per share for the year, up from their prior forecast of ($2.55). Jefferies Financial Group also issued estimates for Cara Therapeutics’ Q4 2021 earnings at ($0.62) EPS, FY2024 earnings at $1.44 EPS and FY2025 earnings at $3.04 EPS.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.12. Cara Therapeutics had a negative net margin of 360.35% and a negative return on equity of 64.36%.
CARA stock opened at $13.20 on Thursday. The stock’s 50 day simple moving average is $21.60 and its 200 day simple moving average is $18.16. Cara Therapeutics has a 12-month low of $11.80 and a 12-month high of $29.65. The firm has a market cap of $660.69 million, a P/E ratio of -6.23 and a beta of 1.70.
In other Cara Therapeutics news, insider Joana Goncalves sold 3,000 shares of the business’s stock in a transaction on Wednesday, April 21st. The shares were sold at an average price of $27.63, for a total value of $82,890.00. Following the sale, the insider now owns 43,610 shares of the company’s stock, valued at approximately $1,204,944.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Derek T. Chalmers sold 3,103 shares of the firm’s stock in a transaction dated Friday, March 5th. The stock was sold at an average price of $17.98, for a total transaction of $55,791.94. Following the transaction, the chief executive officer now directly owns 953,614 shares of the company’s stock, valued at $17,145,979.72. The disclosure for this sale can be found here. In the last three months, insiders sold 36,287 shares of company stock worth $714,394. Insiders own 5.70% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CARA. Strs Ohio acquired a new position in Cara Therapeutics during the 1st quarter worth $47,000. Captrust Financial Advisors boosted its holdings in shares of Cara Therapeutics by 20.0% in the fourth quarter. Captrust Financial Advisors now owns 3,000 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 500 shares during the period. Quantbot Technologies LP raised its holdings in shares of Cara Therapeutics by 3,982.7% during the first quarter. Quantbot Technologies LP now owns 3,062 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 2,987 shares during the period. Freedman Financial Associates Inc. bought a new stake in shares of Cara Therapeutics in the fourth quarter valued at about $82,000. Finally, Acadian Asset Management LLC bought a new position in shares of Cara Therapeutics during the first quarter worth about $145,000. 67.01% of the stock is owned by hedge funds and other institutional investors.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Further Reading: Street Name
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.